Cardium Therapeutics, Inc. Announces Addition Of Vice President - Regulatory Affairs To Advance Commercial Development Of Generx(TM)

SAN DIEGO, Nov. 23 /PRNewswire-FirstCall/ -- Cardium Therapeutics Inc., a wholly-owned subsidiary of Aries Ventures Inc. , announced today the addition of Jennifer A. Spinella as Vice President - Regulatory Affairs.

(Logo: )

Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics said, "We are pleased to welcome Jennifer to Cardium Therapeutics. Jennifer's significant experience in pharmaceutical product development will assist us with the regulatory approval process relating to the commercial development of our lead product, Generx, a DNA-based angiogenic therapeutic."

Ms. Spinella was formerly Director of Regulatory Affairs at Biogen Idec Inc. and was responsible for the regulatory strategy and recent supplemental Biologics License Application (sBLA) for Rituxan(R) in Rheumatoid Arthritis. Before joining Biogen Idec in 2003, she was Director of Regulatory Affairs at Idun Pharmaceuticals Inc. and held various regulatory positions at Elan Pharmaceuticals Inc., Chugai Biopharmaceuticals Inc., Dura Pharmaceuticals Inc. and Gensia Pharmaceuticals Inc. Ms. Spinella earned her B.S. in Medical Technology from the University of Nebraska College of Medicine, Omaha, Nebraska.

About the Company

Cardium Therapeutics Inc. (the Company), headquartered in San Diego, is primarily focused on interventional cardiology and the development and commercialization of non-surgical cardiovascular gene therapeutics. The Company's lead product candidate, Generx(TM), is a non-surgical angiogenic therapy designed to be a one-time treatment for patients with recurrent angina due to coronary artery disease. Generx and the related cardiovascular technology platform were pioneered by Collateral Therapeutics, a San Diego-based biotechnology company co-founded by the Company's CEO Christopher Reinhard. In 1996, Schering AG Germany and Collateral Therapeutics entered into a strategic partnership to develop angiogenic DNA-based therapeutics, including Generx. Based on the advancing clinical progress of Generx, Schering AG acquired Collateral Therapeutics in 2002. In October 2005, the Company announced the acquisition of a portfolio of cardiovascular growth factor therapeutics from Schering AG Germany, including the later-stage product candidate, Generx, and simultaneously merged with a specially formed subsidiary of Aries Ventures Inc. and completed a $30 million financing. For more information about the Company and its product candidates, please visit

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that critical personnel can be retained, that required clinical trials will be successful, that necessary regulatory approvals will be obtained, or that the proposed treatments will prove to be safe or effective. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development of DNA-based cardiovascular therapeutics, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings made by Aries Ventures Inc. with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2005 Cardium Therapeutics, Inc. All rights reserved. Terms of Use

Privacy Policy. Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium Therapeutics, Inc.

Photo: NewsCom: Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comCardium Therapeutics Inc.; Aries Ventures Inc.

CONTACT: Bonnie Ortega, Director, Investor Relations of CardiumTherapeutics Inc., +1-858-436-1018,

Back to news